Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
VYGR 
Voyager Therapeutics Inc (VYGR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/20/2025: VYGR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 40.94% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 03/20/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 200.95M USD | Price to earnings Ratio - | 1Y Target Price 16.1 |
Price to earnings Ratio - | 1Y Target Price 16.1 | ||
Volume (30-day avg) 387176 | Beta 0.99 | 52 Weeks Range 3.56 - 10.66 | Updated Date 03/27/2025 |
52 Weeks Range 3.56 - 10.66 | Updated Date 03/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.13 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-02-26 | When After Market | Estimate -0.3503 | Actual -0.59 |
Profitability
Profit Margin -81.25% | Operating Margin (TTM) -610.05% |
Management Effectiveness
Return on Assets (TTM) -13.99% | Return on Equity (TTM) -24.25% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -22004939 | Price to Sales(TTM) 2.51 |
Enterprise Value -22004939 | Price to Sales(TTM) 2.51 | ||
Enterprise Value to Revenue 0.14 | Enterprise Value to EBITDA 2.59 | Shares Outstanding 55206900 | Shares Floating 45125556 |
Shares Outstanding 55206900 | Shares Floating 45125556 | ||
Percent Insiders 17 | Percent Institutions 63.9 |
Analyst Ratings
Rating 4.91 | Target Price 17.1 | Buy 1 | Strong Buy 10 |
Buy 1 | Strong Buy 10 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Voyager Therapeutics Inc
Company Overview
History and Background
Voyager Therapeutics Inc. was founded in 2014 and is focused on developing gene therapies for neurological diseases. The company has evolved from initial research into developing clinical-stage programs.
Core Business Areas
- Gene Therapy Development: Voyager's core business is the development of gene therapies for neurological disorders. They utilize adeno-associated virus (AAV) vectors to deliver therapeutic genes directly into the brain or spinal cord.
- TRACER AAV Vector Platform: Voyager is developing its proprietary TRACER (Tropism Redirection of AAV by Cell-type-specific Engineering) AAV vector platform, aiming to improve targeting and reduce off-target effects in gene therapy.
Leadership and Structure
The leadership team consists of experienced executives in gene therapy and neuroscience. The organizational structure includes research, development, clinical, and commercial functions.
Top Products and Market Share
Key Offerings
- VY-TAU01: An investigational gene therapy targeting tau protein for the treatment of Alzheimer's disease. Currently, in clinical trials. Market share data is not applicable as it is still in clinical trials. Competitors: Biogen (BIIB), Eli Lilly (LLY), Roche (RHHBY).
- VY-SOD102: An investigational gene therapy targeting SOD1 for the treatment of amyotrophic lateral sclerosis (ALS). Currently, in clinical trials. Market share data is not applicable as it is still in clinical trials. Competitors: Biogen (BIIB), Amylyx Pharmaceuticals (AMLX).
Market Dynamics
Industry Overview
The gene therapy industry is rapidly growing, driven by advancements in vector technology and increasing regulatory acceptance. The neurological disease space is a significant area of focus, with high unmet medical need.
Positioning
Voyager is positioned as a leader in AAV gene therapy for neurological disorders, particularly with its focus on targeted delivery and innovative vector design through TRACER AAV vector platform. It is competing with other gene therapy companies but differentiating itself with its focus on CNS and its novel delivery tech.
Total Addressable Market (TAM)
The total addressable market for gene therapies for neurological disorders is estimated to be billions of dollars, with growth expected in the coming years. Voyager is positioned to capture a portion of this market with its pipeline of therapies.
Upturn SWOT Analysis
Strengths
- Proprietary TRACER AAV vector platform
- Focus on gene therapy for neurological diseases
- Experienced leadership team
- Clinical-stage programs
Weaknesses
- Limited number of products currently on the market
- High R&D expenses and long development timelines
- Dependence on collaborations and partnerships
- Risk of clinical trial failures
Opportunities
- Expansion of pipeline with new gene therapy candidates
- Potential for strategic partnerships and collaborations
- Advancements in vector technology and gene editing
- Growing demand for gene therapies for neurological disorders
Threats
- Regulatory hurdles and changing guidelines
- Competition from other gene therapy companies
- Potential safety concerns with gene therapies
- Intellectual property disputes
Competitors and Market Share
Key Competitors
- BLUE
- CRSP
- EDIT
- ADVM
Competitive Landscape
Voyager's strengths lie in its TRACER platform and CNS focus. Weaknesses include limited marketed products and reliance on partnerships. Competitors have more advanced pipelines.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Voyager's historical growth is characterized by research and development progress and establishing partnerships. The company is currently focused on advancing its clinical-stage programs.
Future Projections: Future growth is dependent on the success of clinical trials and regulatory approvals. Analyst estimates can be found on finance sites.
Recent Initiatives: Focus on advancement of VY-TAU01 and VY-SOD102, improving TRACER AAV vector platform, and establishing collaborations with other companies.
Summary
Voyager Therapeutics is a biotechnology company focused on gene therapies for neurological diseases. Their proprietary TRACER AAV vector platform is a key strength. The company faces challenges related to clinical trial success and competition in the gene therapy space. Strategic partnerships and successful clinical outcomes will be critical for future growth. They should monitor market trends and regulatory developments to stay competitive.
Similar Companies
- BLUE
- CRSP
- EDIT
- ADVM
Sources and Disclaimers
Data Sources:
- Voyager Therapeutics Inc. website
- SEC filings
- Analyst reports
- Market research reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is estimated and subject to change. Investment decisions should be based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Voyager Therapeutics Inc
Exchange NASDAQ | Headquaters Lexington, MA, United States | ||
IPO Launch date 2015-11-11 | President, CEO & Director Dr. Alfred W. Sandrock Jr., M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 172 | |
Full time employees 172 | |||
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. The company's lead clinical candidate is VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes VY1706, tau silencing gene therapy in preclinical trial for treatment of alzheimer's disease; SOD1 silencing gene therapy program for the treatment of ALS in preclinical trial; and vectorized anti-amyloid antibody early research program for the treatment of AD in preclinical trial. The company also develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. In addition, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.